<SEC-DOCUMENT>0001193125-21-140562.txt : 20210429
<SEC-HEADER>0001193125-21-140562.hdr.sgml : 20210429
<ACCEPTANCE-DATETIME>20210429163059
ACCESSION NUMBER:		0001193125-21-140562
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210429
FILED AS OF DATE:		20210429
DATE AS OF CHANGE:		20210429

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Pharvaris N.V.
		CENTRAL INDEX KEY:			0001830487
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40010
		FILM NUMBER:		21871184

	BUSINESS ADDRESS:	
		STREET 1:		J.H. OORTWEG 21
		STREET 2:		2333 CH LEIDEN
		CITY:			LEIDEN
		STATE:			P7
		ZIP:			00000
		BUSINESS PHONE:		31 (0)71 203 6410

	MAIL ADDRESS:	
		STREET 1:		J.H. OORTWEG 21
		STREET 2:		2333 CH LEIDEN
		CITY:			LEIDEN
		STATE:			P7
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Pharvaris, B.V.
		DATE OF NAME CHANGE:	20201029
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d180142d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13A-16</FONT> OR
<FONT STYLE="white-space:nowrap">15D-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of April 2021 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: <FONT STYLE="white-space:nowrap">001-40010</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Pharvaris N.V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>J.H. Oortweg
21 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2333 CH Leiden </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Netherlands </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address
of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&#9744;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PHARVARIS N.V. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;29, 2021, Pharvaris N.V. issued a press release. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference
herein. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>PHARVARIS N.V.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: April&nbsp;29, 2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Berndt Modig</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Berndt Modig</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><A HREF="http://www.sec.gov/Archives/edgar/data/0001708688/000114036121009907/brhc10022115_ex99-1.htm">99.1</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated April&nbsp;29, 2021</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d180142dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g180142dsp0a1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pharvaris Reports Full Year 2020 Financial Results and Provides Business Highlights </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">RAPIDe-1</FONT> clinical trial enrolling, evaluating PHVS416 as an oral <FONT
STYLE="white-space:nowrap">on-demand</FONT> therapy for HAE </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Open IND for the prophylactic evaluation of PHVS416 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Strong pre-IPO cash and cash equivalents balance of &#128;98.6&nbsp;million as of December&nbsp;31, 2020
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Zug, Switzerland, April</B><B></B><B>&nbsp;29, 2021</B> &#150; Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the
discovery and development of novel oral <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">bradykinin-B2-receptor</FONT></FONT> antagonists for the treatment of hereditary angioedema (HAE) and other <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">bradykinin-B2-receptor-mediated</FONT></FONT> indications, today reported financial results for the year ended December&nbsp;31, 2020, and provided recent business highlights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Supported by a strong cash position from our Series C financing in November and our initial public offering in February, Pharvaris remains focused on
advancing new alternatives to injected prophylactic and <FONT STYLE="white-space:nowrap">on-demand</FONT> HAE therapies using tailored formulations of our compound PHA121,&#148; said Berndt Modig, <FONT STYLE="white-space:nowrap">co-founder</FONT>
and chief executive officer of Pharvaris. &#147;Our <FONT STYLE="white-space:nowrap">RAPIDe-1</FONT> Phase 2 clinical study, evaluating our rapid-release product candidate, PHVS416, for the <FONT STYLE="white-space:nowrap">on-demand</FONT> treatment
of HAE attacks, is actively recruiting patients. We plan to evaluate prophylactic treatment of HAE by initiating two studies in 2021: a second Phase 2 study of PHVS416 and a Phase 1 study of PHVS719, our extended-release product candidate.&#148;
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Business Highlights and Updates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pipeline
</I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Initiated patient dosing of PHVS416 for the <FONT STYLE="white-space:nowrap">on-demand</FONT> treatment of
HAE. </B>As previously announced in February 2021, Pharvaris initiated patient dosing in <FONT STYLE="white-space:nowrap">RAPIDe-1,</FONT> a randomized, double-blind, placebo-controlled Phase 2 clinical trial evaluating the safety, efficacy, and
tolerability of PHVS416 in patients with HAE due to <FONT STYLE="white-space:nowrap">C1-inhibitor</FONT> deficiency type 1 and 2. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Phase 2 prophylactic study of PHVS416 to begin in 2021.</B> As previously announced in April 2021, the U.S.
Food and Drug Administration (FDA) has accepted the Company&#146;s Investigational New Drug (IND) application for prophylactic study of PHVS416 in patients with HAE. Pharvaris continues to expect study initiation in 2021. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g180142dsp0a1.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Phase 1 pharmacokinetics study of PHVS719 to begin by the end of 2021. </B>PHVS719 is an extended-release
formulation of PHA121 intended for use in the prophylactic treatment of HAE. The Company expects to initiate a Phase 1 pharmacokinetics study by the end of 2021. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Completed Phase 1 MAD clinical study of PHA121.</B> In January 2021, Pharvaris announced clinical data from
the Company&#146;s Phase 1 multiple-ascending dose study, demonstrating the oral bioavailability of PHA121. PHA121 was well tolerated at all doses studied, with approximately dose-proportional exposure. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Presentations of clinical data of PHA121 at medical conferences. </B>Data detailing PHA121&#146;s
pharmacokinetic (PK), pharmacodynamic (PD), and safety profiles were presented at the 2021 American Academy of Allergy Asthma&nbsp;&amp; Immunology (AAAAI) Virtual Annual Meeting in February 2021 and at the virtual American College of Asthma,
Allergy and Immunology (ACAAI) Annual Scientific Meeting in November 2020. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Corporate </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Completed initial public offering (IPO). </B>In February 2021, Pharvaris completed its IPO of 9,511,075 shares
of common stock at a public offering price of $20.00 per share, generating gross proceeds of $190.2&nbsp;million before deducting underwriting discounts and commissions and estimated offering expenses. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Board of Directors. </B>In January 2021, the Company appointed David Meeker, M.D., and Robert Glassman, M.D.,
to its Board of Directors. Dr.&nbsp;Meeker currently acts as the Chair of the Board. Additionally, Richard Gaster, M.D., Ph.D., partner of venBio, who joined the Company&#146;s Board of Directors in August 2019 as part of Pharvaris&#146; Series B
financing, will transition off of the Board to focus on new investments, effective May&nbsp;1, 2021. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Closed Series C financing. </B>In November 2020, Pharvaris closed an oversubscribed $80&nbsp;million Series C
financing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Upcoming presentations.</B> The Company will participate in the upcoming BofA Securities Virtual Health Care
Conference. Berndt Modig, <FONT STYLE="white-space:nowrap">co-founder</FONT> and chief executive officer of Pharvaris, and Morgan Conn, Ph.D., chief business officer of Pharvaris, will participate in a fireside chat via online video on Wednesday,
May&nbsp;12. The Company will also participate in the upcoming Rare &amp; Orphan Disease Summit, hosted virtually by Oppenheimer on Friday, May 21. Berndt Modig and Morgan Conn will provide a company overview. The virtual presentations will be
available for 30 days on the Pharvaris website at https://ir.pharvaris.com/news-events/events-presentations. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g180142dsp0a1.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Year End 2020 Financial Results </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Liquidity Position. </B>Cash and cash equivalents were &#128;98.6&nbsp;million as of December&nbsp;31, 2020,
as compared to &#128;20.3&nbsp;million as of December&nbsp;31, 2019. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Research and Development (R&amp;D) Expenses. </B>R&amp;D expenses were &#128;19.5&nbsp;million for the full
year ended December&nbsp;31, 2020, compared to &#128;5.7&nbsp;million for the year ended December&nbsp;31, 2019.<B> </B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>General and Administrative (G&amp;A) Expenses</B>. G&amp;A expenses were &#128;5.5&nbsp;million for the full
year ended December&nbsp;31, 2020, compared to &#128;2.3&nbsp;million for the year ended December&nbsp;31, 2019. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Loss for the year. </B>Loss for the year was &#128;26.0&nbsp;million, or basic and diluted loss per share of
&#128;5.36, for the year ended December&nbsp;31, 2020, compared to loss for the year of &#128;8.0&nbsp;million, or basic and diluted loss per share of &#128;1.66 for the year ended December&nbsp;31, 2019. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note on International Financial Reporting Standards (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pharvaris is a Foreign Private Issuer and prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by
the International Accounting Standards Board. Pharvaris maintains its books and records in the Euro currency. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Pharvaris </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pharvaris is a clinical-stage company focused on bringing oral
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">bradykinin-B2-receptor</FONT></FONT> antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new
alternatives to injected therapies for all <FONT STYLE="white-space:nowrap">sub-types</FONT> of HAE and other bradykinin-mediated diseases. The Company brings together executives with a breadth of expertise across pharmaceutical development and rare
disorders, including HAE. For more information, visit https://pharvaris.com/. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About PHVS416 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PHVS416 is a softgel capsule formulation containing PHA121, a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2
receptor. Pharvaris is developing this formulation to provide rapid exposure of attack-mitigating medicine in a convenient, small oral dosage form. PHVS416 is currently in Phase 2 clinical development for the
<FONT STYLE="white-space:nowrap">on-demand</FONT> treatment of HAE. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About PHVS719 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PHVS719 is an extended-release tablet formulation containing PHA121, a highly potent, specific, and orally bioavailable competitive antagonist of the
bradykinin B2 receptor. Pharvaris is developing this formulation to provide sustained exposure of attack-preventing medicine in a convenient, small oral dosage form. PHVS719 is currently in preclinical development for the prophylactic treatment of
HAE. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g180142dsp0a1.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About PHA121 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PHA121 <FONT STYLE="white-space:nowrap">(PHA-022121)</FONT> is a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2
receptor that has completed Phase 1 clinical development for the treatment of HAE. PHA121 utilizes the same mechanism as icatibant, the leading therapy for <FONT STYLE="white-space:nowrap">on-demand</FONT> treatment of HAE. Pharvaris is developing
this novel small molecule for <FONT STYLE="white-space:nowrap">on-demand</FONT> and prophylactic treatment of HAE and other bradykinin-mediated diseases through formulations optimized for each setting. Data from single- and multiple-ascending-dose
Phase 1 studies in healthy volunteers demonstrate rapid exposure and predictable linear pharmacokinetics at doses up to 50 mg. In a bradykinin-challenge study in healthy volunteers, PHA121 showed significant inhibition of bradykinin-induced
hemodynamic changes with an average composite EC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB> of 2.4 ng/mL and EC<SUB STYLE="font-size:85%; vertical-align:bottom">85</SUB> of 13.8 ng/mL, approximately four-fold more potent than
historical data for icatibant. Quantitative modeling indicates that single oral doses of PHA121 will maintain pharmacologically active drug levels for a substantially longer time than 30 mg of subcutaneous icatibant. PHA121 has been observed to be
well-tolerated at all doses studied to date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains certain forward-looking statements that involve substantial risks and uncertainties. All statements contained in this press release
that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements containing the words &#147;believe,&#148; &#147;anticipate,&#148; &#147;expect,&#148; &#147;estimate,&#148;
&#147;may,&#148; &#147;could,&#148; &#147;should,&#148; &#147;would,&#148; &#147;will,&#148; &#147;intend&#148; and similar expressions. These forward-looking statements are based on management&#146;s current expectations, are neither promises nor
guarantees, and involve known and unknown risks, uncertainties and other important factors that may cause Pharvaris&#146; actual results, performance or achievements to be materially different from its expectations expressed or implied by the
forward-looking statements. Such risks include but are not limited to the following: the expected timing, progress, or success of our clinical development programs, especially for PHVS416 and PHVS719, which are in early-stage clinical trials; risks
associated with the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, which may adversely impact our business, preclinical studies, and clinical trials; the timing of regulatory approvals; the value of our ordinary shares; the timing, costs
and other limitations involved in obtaining regulatory approval for our product candidates PHVS416 and PHVS719, or any other product candidate that we may develop in the future; our ability to establish commercial capabilities or enter into
agreements with third parties to market, sell, and distribute our product candidates; our ability to compete in the pharmaceutical industry and with competitive generic products; our ability to market, commercialize and
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g180142dsp0a1.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
achieve market acceptance for our product candidates; our ability to raise capital when needed and on acceptable terms; regulatory developments in the United States, the European Union and other
jurisdictions; our ability to protect our intellectual property and <FONT STYLE="white-space:nowrap">know-how</FONT> and operate our business without infringing the intellectual property rights or regulatory exclusivity of others;&nbsp;our ability
to manage negative consequences from changes in applicable laws and regulations, including tax laws, our ability to successfully remediate the material weakness in our internal control over financial reporting and to maintain an effective system of
internal control over financial reporting; and the other factors described under the heading &#147;Risk Factors&#148; in our registration statement on Form <FONT STYLE="white-space:nowrap">20-F</FONT> and other periodic filings with the Securities
and Exchange Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These and other important factors could cause actual results to differ materially from those indicated by the forward-looking
statements made in this press release. Any such forward-looking statements represent management&#146;s estimates as of the date of this press release. New risks and uncertainties may emerge from time to time, and it is not possible to predict all
risks and uncertainties. While Pharvaris may elect to update such forward-looking statements at some point in the future, Pharvaris disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking
statements should not be relied upon as representing Pharvaris&#146; views as of any date subsequent to the date of this press release. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor
Contact </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mike Biega, Solebury Trout </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>mbiega@soleburytrout.com </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+1-617-221-9660</FONT></FONT></FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Maggie Beller, Russo Partners, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>maggie.beller@russopartnersllc.com </U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+1-646-942-5631</FONT></FONT></FONT> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g180142dsp0a1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g180142dsp0a1.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MHX90NV3<#\WITKHP>.6'BX25T<>8Y4\7-5(.SZE?P[X1U'0M46Y%["\1!61
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MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
2"@ H * "@ H * "@ H * /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
